Metabolic markers in blood can separate prostate cancer from benign prostatic hyperplasia.

Although the classification models separating cancer patients and BPH controls were highly significant, none of the individual metabolites were significantly different between the groups after correcting for multiple testing by the false discovery rate approach.

also in 132,142 other papers

The listed pathways were significant before multiple testing corrections, while the results approached significance after multiple testing corrections ( q =0.099).

also in 8,237 other papers